Detalhe da pesquisa
1.
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Blood
; 143(19): 1931-1936, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364112
2.
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Blood
; 143(4): 336-341, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647641
3.
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Blood
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691678
4.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Blood
; 135(9): 680-688, 2020 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932839
5.
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Br J Haematol
; 192(6): 1026-1030, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32458446
6.
The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.
Biochim Biophys Acta Mol Cell Res
; 1865(1): 105-116, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28939057
7.
Assessment of Minimal Residual Disease in Standard-Risk AML.
N Engl J Med
; 374(5): 422-33, 2016 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26789727
8.
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.
Blood
; 140(22): 2407-2411, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960851
9.
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.
Blood
; 127(1): 29-41, 2016 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26660431
10.
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Blood
; 125(19): 2985-94, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25805812
11.
Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
Br J Haematol
; 164(3): 366-75, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24422723
12.
Assessment of Minimal Residual Disease in Standard-Risk AML.
N Engl J Med
; 375(6): e9, 2016 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27509124
13.
Exercise volume and intensity: a dose-response relationship with health benefits.
Eur J Appl Physiol
; 114(8): 1563-71, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24770699
14.
NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
Genes Chromosomes Cancer
; 52(11): 1053-64, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23999921
15.
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
J Clin Oncol
; : JCO2301599, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427924
16.
Cellular distribution of IDH mutations in AML during morphologic remission.
Leuk Res
; 124: 106993, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36459762
17.
Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Transplant Cell Ther
; 29(7): 454.e1-454.e8, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36966870
18.
Physiological demands of downhill mountain biking.
J Sports Sci
; 30(16): 1777-85, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23025296
19.
Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative.
Pathology
; 53(4): 487-492, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33272691
20.
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.
Blood Adv
; 5(23): 5107-5111, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34555849